RxDoctor Payments Data

Justin Tannir, MD

Ophthalmology · Traverse City, MINPI 1578740668

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (40.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 63.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $11,700 and has fallen 93.1% since, to $808 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,204in general payments, 2019–2025

Across 243 payments — averaging $87.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Alcon$2K
  • Rxsight Inc$2K
  • Johnson & Johnson Surgical Vision, Inc.$998
  • Bausch & Lomb Americas Inc.$461
  • Genentech USA, Inc.$272
  • plus $2K from 24 others
$5in research payments, 2019–2025

Across 1 payment — averaging $5.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$5

What the payments were for

  • Speaking & faculty fees$8,21339%
  • Travel & lodging$2,88014%
  • Food & beverage$8,56540%
  • Education$1,5477%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,204 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$425,415
Medicare patients
605
Services billed
4,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost167$82,713
RestasisCyclosporine54$60,003
Bromfenac Sodium159$38,233
Bimatoprost192$28,212
Cyclosporine36$24,854
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol112$22,918
RocklatanNetarsudil Mesylat/Latanoprost49$21,548
CombiganBrimonidine Tartrate/Timolol57$20,747
ProlensaBromfenac Sodium53$17,851
SimbrinzaBrinzolamide/Brimonidine Tart64$17,152
Travoprost79$13,467
Brimonidine Tartrate322$7,294
Restasis MultidoseCyclosporine12$7,236
Latanoprost384$6,726
TafluprostTafluprost/Pf21$6,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Restasis Multidose$13,368$170,700290 claims
Aerie Pharmaceuticals, Inc.Rocklatan$222$21,54849 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$198$17,85153 claims
AlconSimbrinza$1,963$17,15264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →